Responses
Poster Presentations
Rheumatoid arthritis - comorbidity and clinical aspects
SAT0117 Retention rates of adalimumab, etanercept, and infliximab as 1st- or 2nd-line biotherapy for rheumatoid arthritis patients in daily practice in auvergne
Compose a Response to This Article
Other responses
No responses have been published for this article.